Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Return on Sales (2022 - 2025)

Bioregenx has reported Return on Sales over the past 4 years, most recently at 0.03% for Q4 2025.

  • For Q4 2025, Return on Sales rose 37.0% year-over-year to 0.03%; the TTM value through Dec 2025 reached 0.01%, up 8.0%, while the annual FY2025 figure was 0.01%, 9.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.03% at Bioregenx, down from 0.0% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.0% in Q3 2023 and troughed at 0.4% in Q4 2024.
  • A 4-year average of 0.04% and a median of 0.01% in 2024 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: tumbled -39bps in 2024 and later soared 37bps in 2025.
  • Year by year, Return on Sales stood at 0.01% in 2022, then plummeted by -71bps to 0.01% in 2023, then tumbled by -3663bps to 0.4% in 2024, then surged by 93bps to 0.03% in 2025.
  • Business Quant data shows Return on Sales for BRGX at 0.03% in Q4 2025, 0.0% in Q3 2025, and 0.0% in Q2 2025.